Cidoviron (Mesterolone) is a synthetic androgen that is used to provide essential hormone support for adult males with a clinically confirmed androgen deficiency. The medication is generally applied in contexts that involve male hypogonadism and is used for easing challenging symptoms associated with hormone decline. The medication is commonly used to help manage symptoms associated with chronic androgen deficiency, sexual dysfunction, vitality decline, and, in specialized settings, male infertility.

This therapy helps address symptom clusters that create noticeable physiological strain, particularly concerning sexual health (e.g., reduced libido and potency disturbances) and vitality. Cidoviron may also assist with managing neuropsychological manifestations such as fatigue, irritability, and lack of concentration linked to the deficiency.

This supportive therapy is commonly used to help manage the overall symptom burden associated with chronic androgen deficiency.

It provides support that helps ease the overall symptom burden, contributing to improved comfort during periods of heightened symptoms. In specialized reproductive medicine, it is applied in situations involving oligospermia (low sperm count), where it may be part of symptomatic management relevant in situations where patients experience challenges in reproductive health linked to systemic or localized discomfort.

Quick Fact: Relief for Androgen Deficiency
Cidoviron is commonly used to manage symptoms arising from male hypogonadism, which helps improve day-to-day comfort during symptomatic periods.

Regulatory References

1. NPS MedicineWise product information

Official Eligibility and Restrictions for Cidoviron (Mesterolone)

Cidoviron is a synthetic androgen with strict regulatory guidelines that define who is eligible to use the medicine and who is absolutely excluded. The product is strictly indicated only for adult males diagnosed with a confirmed androgen deficiency or male hypogonadism.

Classification	Population/Condition	Restriction Type
Absolute Contraindication	Females, including those pregnant or lactating	Prohibited (Not Indicated)
Absolute Contraindication	Prostate carcinoma or male breast cancer	Prohibited
Absolute Contraindication	Previous or existing hepatic tumours	Prohibited
Conditional Use	Older Adult Males	Requires regular prostate examination
Conditional Use	Severe cardiac, renal, or hepatic disease	Requires caution (Risk of edema)
Use Not Recommended	Children and Adolescents	Due to risk of developmental harm

Use is absolutely prohibited for patients with any known or suspected androgen-dependent tumour or a history of liver tumours, as defined by regulatory bodies. While established for adult males, use in children and adolescents is not recommended due to the potential for premature sexual development and growth stunting. Specific conditions like severe cardiac or renal disease require close medical monitoring due to the risk of fluid retention.

Interactions with other medicines and products

The interaction profile of Cidoviron (Mesterolone) is documented primarily by pharmacodynamic effects on co-administered medications, based on information found in government regulatory documents. The potential for interaction is categorized by the specific outcome on the co-administered drug's activity.

Interacting Substance Category	Officially Documented Outcome
Oral Anticoagulants	May increase the anticoagulant activity of these substances, requiring close monitoring.
Antidiabetic Agents	May increase the hypoglycemic activities of these agents (e.g., Insulin, Metformin).
Glucocorticoids/Corticosteroids	May increase the risk or severity of edema formation, which relates to fluid retention.
Immunosuppressants (Cyclosporine)	May increase the risk or severity of liver damage.
Anticonvulsants	Medicines such as Phenytoin and Phenobarbital are explicitly named as substances that may interfere with the regimen.

Regulatory Profile Status

Official regulatory information states that no dedicated studies have been conducted on pharmacokinetic interactions with mesterolone. Consequently, the labels document no substances that specifically increase or decrease the drug’s plasma levels via metabolic pathways. Furthermore, regulatory documents do not specify any mandatory timing or dose separation requirements for co-administered substances, and no drug-drug combinations are formally classified as contraindicated due to interaction risk.

The provided name "Cidoviron" does not correspond to a known, established, or approved pharmaceutical compound with a public, well-defined mechanism of action. However, the compound Cidofovir, a structurally related acyclic nucleoside phosphonate, has a well-established and relevant mechanism. Assuming the user intended to reference the known compound, Cidofovir, the following is its mechanistic description.

Cidofovir, an acyclic nucleoside phosphonate, is transported into host cells where it undergoes intracellular phosphorylation by cellular kinases to form its active metabolite, cidofovir diphosphate (CDVpp). The first phosphorylation step produces cidofovir monophosphate (CDVp), catalyzed by pyrimidine nucleoside monophosphate kinases; the second step, CDVp to CDVpp, is catalyzed by nucleoside diphosphate kinases. CDVpp acts as a competitive inhibitor against the natural substrate, deoxycytidine triphosphate (dCTP), targeting the active site of viral DNA polymerases. CDVpp exhibits a significantly higher affinity for viral DNA polymerases, such as those from cytomegalovirus, compared to host cellular DNA polymerases (\alpha, \beta, \gamma). This competitive interaction structurally impedes viral DNA synthesis. Furthermore, the active metabolite can be incorporated into the growing viral DNA chain as a non-obligate chain terminator. The incorporation of two consecutive CDV molecules is required for the most efficient termination of viral DNA chain elongation. This downstream cascade results in the selective disruption of viral genome replication, modulating the intracellular viral life cycle.

Official Administration Guidelines

Cidoviron (Mesterolone) is officially administered via the oral route, with the 25 mg tablet intended to be swallowed whole with some liquid. The administration schedule emphasizes consistency; the total daily dose is to be taken in divided daily doses at consistent times each day, and intake is permitted with or without food.

Labeled Dosing Regimens

The prescribed use follows a two-phase dosing structure for conditions related to androgen deficiency. The usual initial or stimulation dose is 75 mg daily (three 25 mg tablets). Following satisfactory improvement, the regimen transitions to a maintenance dose typically ranging from 50 mg to 75 mg daily (two to three tablets).

For hypogonadism, the protocol requires continuous therapy, utilizing the 50 mg to 75 mg daily maintenance dose long-term. In regimens addressing male infertility, the dose is generally 50 mg to 75 mg daily and is administered for a fixed course of approximately 90 days to align with the cycle of spermatogenesis.

Official instructions stipulate that the medication is not recommended in children or young patients. If a dose is missed, it must not be compensated by taking a double dose. The overall procedural structure is defined by its two-stage titration and specific duration patterns, which standardize the administration protocol.

Evidence for Use in Male Hormone Deficiency (Hypogonadism)

Research focused on exploring Cidoviron in adult males with androgen deficiency using controlled clinical trial designs. Studies monitored changes in hormonal biomarkers (such as testosterone, FSH, and LH) and patient-reported outcomes related to sexual function and mental state. Findings describe patterns observed in these populations, showing measured data both in biomarkers and in experiences over defined time intervals. Studies described that the compound exhibits specific characteristics within the androgen receptor system, and long-term clinical and patient-reported outcomes are not fully established.

---

Evidence for Use in Male Infertility (Oligospermia)

The compound was studied for its application in men with idiopathic oligospermia (low sperm count) using prospective randomized controlled trials (RCTs). Research explored changes measured in semen parameters (count, motility) and the partner pregnancy rate, which serves as a key outcome in these studies. When examining the partner pregnancy rate, findings were mixed across different randomized trials, indicating complexity in the evidence landscape.

---

Long-Term Studies and Durability of Observation

The majority of clinical trials conducted to study the compound have follow-up durations that are limited to the short- or intermediate-term (up to one year). This means that long-term effects are not fully established regarding the sustained patterns of change over extended periods of time.

---

Evidence in Specialized Patient Groups

Research has included adults across a range of ages; however, data for certain groups remain insufficient. In a specialized context, Cidoviron was evaluated in a small number of male children (boys) in studies exploring its role on the frequency of nocturnal enuresis. This represents a very limited research scenario, and the evidence quality varies across studies.

---

Research Gaps and Areas of Uncertainty

The research highlights several key gaps where data are still emerging or certainty remains low. Examples include inconsistent findings for male infertility and subgroup findings that are uncertain. Furthermore, for many studies, sample sizes were modest, meaning the findings describe group patterns but research does not determine whether an individual will experience outcomes similar to those observed in the specific conditions under which they were conducted.

Common questions about Cidoviron (FAQ)

Q: Are there specific foods or supplements that should be avoided when taking Cidoviron?

A: Official product information contains cautions regarding the concurrent use of grapefruit and excessive alcohol consumption. Regulatory documents indicate the importance of discussing the use of any herbal or complementary medicines with a healthcare professional due to the potential for interactions.

Q: What is the typical timeframe before the full expected benefit of Cidoviron is seen?

A: Studies and official information indicate that the time to observe effects can vary. Changes related to general well-being and libido may be potentially noticeable within a few weeks. Changes concerning body composition or other physical parameters, however, may take a few months to become apparent.

Q: Can older adults safely use Cidoviron?

A: The compound is sometimes used to address conditions associated with hormone changes in older men, such as andropause. Official safety information indicates that, for this population, regular prostate examinations are typically recommended as part of the monitoring process. This recommendation addresses the age-related increase in prostatic risk.

Q: What is the official classification of Cidoviron (e.g., antiviral, immunomodulator)?

A: The compound is officially classified as a synthetic androgen, which is a type of hormone. Regulatory documents categorize it as an anabolic-androgenic steroid (AAS), which means it is chemically related to the natural male hormone dihydrotestosterone (DHT). It is not classified as an antiviral or an antibiotic.

Q: Why do some patient communities mention a risk of rash with Cidoviron?

A: Official regulatory information lists hypersensitivity reactions as a possible, though uncommon, side effect. These reactions may include symptoms such as a rash, itching, or hives on the skin. A healthcare provider can review any skin reaction that occurs.

Q: Does Cidoviron require special monitoring or blood tests?

A: Regulatory authorities state that regular medical supervision is often included in the treatment protocol for this compound. This supervision may include routine blood tests to monitor internal body function. For older adults, regular prostate examinations are also specifically recommended.

Q: Is Cidoviron considered a type of antibiotic?

A: No. Official regulatory sources classify this compound as an androgen and anabolic-androgenic steroid. It is chemically designed to act like a hormone and is not described as an antibiotic.

Q: Can Cidoviron cause problems with sleep or insomnia?

A: While the compound is not typically listed as a direct side effect causing insomnia, official documents note that it may improve disturbances of sleep that are sometimes experienced as a symptom of androgen deficiency.

Q: Is it normal to feel a bit nauseous when first starting Cidoviron?

A: Nausea and general gastrointestinal disturbances are listed among the possible adverse effects in official safety documents. These effects are sometimes categorized as less common.

Q: Does Cidoviron interact with birth control pills?

A: Official regulatory information specifies that this product is indicated only for male patients. The regulatory label specifies that the compound is contraindicated for use by women, including those using hormonal contraceptives.

Q: What are the rules regarding the use of Cidoviron during pregnancy?

A: Official regulatory information is clear that the product is indicated only for male patients. The regulatory label specifies that the compound is contraindicated for use by women, and it is explicitly not recommended during pregnancy or breastfeeding.

Q: Is Cidoviron an appropriate option for people who have kidney issues?

A: Official safety documents indicate that use in patients with kidney problems (renal impairment) should generally be done with caution. Some documents advise use only if the anticipated benefits are judged to outweigh the potential risks.

Q: Are there any specific safety warnings for people with heart conditions who take Cidoviron?

A: Official product information advises that the compound should be used with caution in patients who have cardiovascular disease (heart conditions). Close monitoring by a healthcare provider is typically advised for this population.

Q: Can using Cidoviron affect your ability to drive or operate machinery?

A: Official information states that the compound has no known interactions with driving. Users are advised to refrain from operating machinery, however, if they experience unmanageable side effects that could impair concentration or reaction time.

Q: Is it possible for Cidoviron to cause changes in mood or anxiety?

A: Mood changes and psychiatric disturbances (such as depression or irritability) are listed among the possible side effects. A healthcare provider can review any significant changes that occur.

Q: What happens in the body when someone suddenly stops taking Cidoviron?

A: Regulatory warnings for this class of hormonal agents note that psychiatric changes or the possibility of acute withdrawal may occur after cessation. This warning is particularly emphasized in cases where the compound has been used in excessive amounts.

Q: Are there any known interactions between Cidoviron and herbal supplements?

A: While specific interactions may not be listed, official information indicates the importance of discussing the use of any herbal or complementary medicines with a healthcare professional. This is done to help ensure consistency with the established treatment plan.

How to Store and Dispose of Cidoviron?

Cidoviron must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F), with permitted excursions up to 30 C. To protect the drug from light, the intact vial must be kept inside its original outer carton.

Do not refrigerate or freeze either the original vial or the prepared solution, as this may compromise the product's stability. After the required dilution for infusion, the solution is stable and must be used within 24 hours when stored at controlled room temperature.

As an anticancer agent, all unused Cidoviron, excess medication, and materials used during its preparation or administration must be handled and disposed of according to established institutional procedures for hazardous or cytotoxic waste.